Author:
Döring Yvonne,Noels Heidi,van der Vorst Emiel P.C.,Neideck Carlos,Egea Virginia,Drechsler Maik,Mandl Manuela,Pawig Lukas,Jansen Yvonne,Schröder Katrin,Bidzhekov Kiril,Megens Remco T.A.,Theelen Wendy,Klinkhammer Barbara M.,Boor Peter,Schurgers Leon,van Gorp Rick,Ries Christian,Kusters Pascal J.H.,van der Wal Allard,Hackeng Tilman M.,Gäbel Gabor,Brandes Ralf P.,Soehnlein Oliver,Lutgens Esther,Vestweber Dietmar,Teupser Daniel,Holdt Lesca M.,Rader Daniel J.,Saleheen Danish,Weber Christian
Abstract
Background:
The CXCL12/CXCR4 chemokine ligand/receptor axis controls (progenitor) cell homeostasis and trafficking. So far, an atheroprotective role of CXCL12/CXCR4 has only been implied through pharmacological intervention, in particular, because the somatic deletion of the
CXCR4
gene in mice is embryonically lethal. Moreover, cell-specific effects of CXCR4 in the arterial wall and underlying mechanisms remain elusive, prompting us to investigate the relevance of CXCR4 in vascular cell types for atheroprotection.
Methods:
We examined the role of vascular CXCR4 in atherosclerosis and plaque composition by inducing an endothelial cell (BmxCreER
T2
-driven)–specific or smooth muscle cell (SMC, SmmhcCreER
T2
- or TaglnCre-driven)–specific deficiency of
CXCR4
in an apolipoprotein E–deficient mouse model. To identify underlying mechanisms for effects of CXCR4, we studied endothelial permeability, intravital leukocyte adhesion, involvement of the Akt/WNT/β-catenin signaling pathway and relevant phosphatases in VE-cadherin expression and function, vascular tone in aortic rings, cholesterol efflux from macrophages, and expression of SMC phenotypic markers. Finally, we analyzed associations of common genetic variants at the
CXCR4
locus with the risk for coronary heart disease, along with
CXCR4
transcript expression in human atherosclerotic plaques.
Results:
The cell-specific deletion of
CXCR4
in arterial endothelial cells (n=12–15) or SMCs (n=13–24) markedly increased atherosclerotic lesion formation in hyperlipidemic mice. Endothelial barrier function was promoted by CXCL12/CXCR4, which triggered Akt/WNT/β-catenin signaling to drive VE-cadherin expression and stabilized junctional VE-cadherin complexes through associated phosphatases. Conversely, endothelial
CXCR4
deficiency caused arterial leakage and inflammatory leukocyte recruitment during atherogenesis. In arterial SMCs, CXCR4 sustained normal vascular reactivity and contractile responses, whereas
CXCR4
deficiency favored a synthetic phenotype, the occurrence of macrophage-like SMCs in the lesions, and impaired cholesterol efflux. Regression analyses in humans (n=259 796) identified the C-allele at
rs2322864
within the
CXCR4
locus to be associated with increased risk for coronary heart disease. In line, C/C risk genotype carriers showed reduced CXCR4 expression in carotid artery plaques (n=188), which was furthermore associated with symptomatic disease.
Conclusions:
Our data clearly establish that vascular CXCR4 limits atherosclerosis by maintaining arterial integrity, preserving endothelial barrier function, and a normal contractile SMC phenotype. Enhancing these beneficial functions of arterial CXCR4 by selective modulators might open novel therapeutic options in atherosclerosis.
Publisher
Ovid Technologies (Wolters Kluwer Health)
Subject
Physiology (medical),Cardiology and Cardiovascular Medicine